The Global Chromoblastomycosis Working Group (GCWG) invites you to join an engaging session on chromoblastomycosis to provide updates on achieving activities identified to address chromoblastomycosis, a neglected tropical disease, globally. The GCWG was formed in 2024 to lead control efforts of chromoblastomycosis including the development of a global strategy. The GCWG will host this workshop to discuss ongoing initiatives that align with the GCWG global strategy, and provide novel data on epidemiological, diagnostic, clinical, and laboratory aspects of chromoblastomycosis. Topics to be discussed include diagnosing chromoblastomycosis at the primary care level and decentralized sites, the development and role of epidemiological cutoff values for chromoblastomycosis-causing fungi, antifungal susceptibility testing using muriform bodies (sclerotic cells), therapeutic options including newer azoles and topical immunomodulators, monitoring for geographical spread of climate-sensitive causative organisms, and defining the true burden of disease through quality of life and disability studies.
We look forward to welcoming you and your participation!
Organizing Committee:
Global Chromoblastomycosis Working Group
Program
10:30 hrs Global Chromoblastomycosis Strategy Overview and Progress Achieved
Dallas Smith (USA)
10:45 hrs PK/PD and access to itraconazole
Francelise Bridi Cavassin (Brazil)
11:00 hrs Susceptibility profile of Fonsecaea species and establishment of epidemiological cutoff values
Daniel Wagner (Brazil)
11:15 hrs Conducting AFST with muriform cells in a skin 3D model
Bruna Jacomel (Brazil)
11:30 hrs Utilizing tele-dermatology and training of community health workers to diagnose chromoblastomycosis in Indonesia
Marlous Grijsen (Indonesia)
11:45 hrs The treatment of chromoblastomycosis with imiquimod
Conceição Azevedo (Brazil)
12:00 hrs Abstract presenter
12:15 hrs Skin NTD outreach in Paraguay
Jose Brunelli Pereira (Paraguay)